Information from Industry - Sponsored Supplement

Omadacycline: An Oral Antibiotic for the Treatment of Bacterial Skin Infections and Pneumonia in an Era of Unmet Clinical Need

J Fam Pract. 2022 June;71(5)
This supplement was sponsored by Paratek Pharmaceuticals, Inc. It was edited and peer reviewed by The Journal of Family Practice.

 

Despite advances in the management of skin and soft tissue infections and community-acquired pneumonia, challenges persist. This 2-part supplement to The Journal of Family Practice summarizes the findings of 3 phase 3 studies of omadacycline.
 

 

Read More

 

 

Recommended Reading

EULAR recommends starting methotrexate and glucocorticoids in RA management
MDedge Family Medicine
High maternal, fetal morbidity rates in SLE pregnancies
MDedge Family Medicine
NIAID trial to test asthma drug in disadvantaged urban children
MDedge Family Medicine
Surgeons, who see it up close, offer ways to stop gun violence
MDedge Family Medicine
ECDC gives guidance on prevention and treatment of monkeypox
MDedge Family Medicine
Will tirzepatide slow kidney function decline in type 2 diabetes?
MDedge Family Medicine
Tirzepatide powers ‘unprecedented’ weight loss in SURMOUNT-1
MDedge Family Medicine
Weekly dulaglutide promising in youth with type 2 diabetes
MDedge Family Medicine
Mohs surgery in the elderly: The dilemma of when to treat
MDedge Family Medicine
Trans teens less likely to commit acts of sexual violence, says new study
MDedge Family Medicine